Use of bioregulatory osteoprotectors in the elderly to reduce the drug load in diseases of the musculoskeletal system

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

By the example of the use of bioregulatory nutraceutical «Osteomed Forte» shows the possibility of reducing the drug load on the body in the treatment of comorbid pathologies of the elderly-osteoporosis, sarcopenia, arthritis, arthrosis, periodontitis, etc.

Full Text

Restricted Access

About the authors

Dmitry G. Elistratov

«Parafarm» Ltd

Author for correspondence.
Email: dge117@mail.ru

General director

Russian Federation, Penza

References

  1. Comorbid Pathology in Clinical Practice. Clinical guidelines. Cardiovascular Therapy and Prevention, 2017; 16(6): 5–56. http://dx.doi.org/10.15829/1728-8800-2017-6-5-56
  2. Khabibulina M.M., Shamilov M.D. Effect of Femo-Clim on quality of life in young women with altered hormonal background. Phys. 2022 Т. 33. № 3. С. 12-16. https://doi.org/10.29296/25877305-2022-03-02
  3. Khabibulina M.M., Shamilov M.D. Quality of life in young women with arterial hypertension and altered hormonal background. Phys. 2021 Т. 32. № 1. С. 46-49. https://doi.org/10.29296/25877305-2021-01-09
  4. Melnichenko G.A., Belaya J.E., Rozhinskaya L.Y., et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Problems of Endocrinology. 2017; 63(6): 392–426.
  5. Strukov V., Kislov A., Elistratov D. et al. Personalized approach in the therapy of osteoporosis in the elderly. Phys. 2015; 6: 51–3.
  6. Pavlova T., Bashuk I. Clinical and morphological features of degenerative changes in bone tissue against osteoporosis in the age aspect. Phys. 2019; 30 (6): 47–50. https://doi.org/10.29296/25877305-2019-06-11
  7. Strukov V., Elistratov D., Kislov A. et al. Osteoporosis in geriatric practice. Physician. 2018; 29 (6): 26–30. https://doi.org/10.29296/25877305-2018-06-05
  8. Dedov, D. V. Risk of recurrence of atrial fibrillation in patients with coronary heart disease and arterial hypertension according to Holter electrocardiogram monitoring. Bulletin of Arrhythmology. 2010; 59: 27–32.
  9. Anosova E., Filimonov M., Proshchaev K., Romanchikov A. Polymorbidity – polypragmasia – deprescribing: current trends in pharmacotherapy of geriatric patients and its optimization. Physician. 2019; 6: 17–23. doi: 10.29296/25877305-2019-06-04
  10. Dedov D., Mukailov N., Evtyukhin I. Quality of life and prognosis in patients with AH and CHD with atrial fibrillation. Phys. 2013; ? 7: 72–74.
  11. Dedov D.V., Mazaev V.P., Ryazanova S.V. et al. Study of quality of life in interventional and conservative treatment of patients with stable angina pectoris at long-term follow-up. Cardiovascular Therapy and Prevention. 2014; 13(5): 31–35.
  12. Dedov D.V., Ivanov A.P., Elgardt I.A. Treatment of arrhythmia in patients with arterial hypertension. Clinical Medicine. 2012; 90 (6): 39–42.
  13. Dedov D., Mukailov N., Evtyukhin I. Potassium and magnesium preparations in comprehensive prevention of complications of arterial hypertension and ischemic heart disease. Phys. 2013; 8: 45–46.
  14. Dedov D., Mukailov N., Evtyukhin I., Kovalchuk A., Bogdanova N. Preduktal MV in the treatment and prevention of cardiovascular complications in patients with CHD. Phys. 2013; ? 12: 40–41.
  15. Sychev DA, Otdelenov VA, Krasnova NM, Ilyina E. С. Polypragmasia: the view of a clinical pharmacologist. Therapeutic Archives. 2016; 12: 94–102.
  16. Dedov D., Mukailov N., Evtyukhin I. Combination of amlodipine and atorvastatin in reducing the risk of cardiovascular complications. Phys. 2013; 3: 18–19
  17. Dedov D.V. Effect of electromechanical remodeling of the heart on the development of atrial fibrillation in patients with CHD and arterial hypertension. Russian Journal of Cardiology. 2011; 16 (4): 13–18.
  18. Evtyukhin I.Y., Ryazanova S.V., Dedov D.V. et al. Comparison of quality-of-life parameters in the long-term period of interventional treatment of patients with coronary heart disease. Modern problems of science and education. 2015; 6: 145. doi: 10.17513/spno.23336
  19. Dedov D.V. Evaluation of quality of life parameters in the absence and at recurrence of angina pectoris in men with stable coronary heart disease at long-term follow-up after percutaneous coronary intervention. Preventive Medicine. 2021; 24 (5–2): 63.
  20. Trifonov V., Elistratov D. Recommendations for the treatment of osteoporosis in conditions of comorbidity and polypragmasy with Osteomed forte and phytopreparations. Physician. 2018; (5): 87–88.
  21. Sychev D.A. Polypragmasy in clinical practice: problems and solutions: tutorial. М.; 2016; 250.
  22. Lubenets A. Treatment of injuries of the proximal femur in elderly patients. Phys. 2017; 7: 65–67.
  23. Clinical recommendations «Osteoporosis». Approved by the Ministry of Health of Russia, 2021; 82 p.
  24. Dedov, D. V. Osteoporosis in elderly patients: prevalence, pathogenesis, clinic, prevention of complications. Phys. 2021; 32 (7): 82–85. https://doi.org/10.29296/25877305-2021-07-14
  25. Yarmolovich R.A., Salaev A.V. Improvement of regenerative capacity of bone tissue at diaphyseal fractures of tubular bones on the background of Osteomed Forte application. Phys. 2020; 31 (5): 63–6. https://doi.org/10.29296/25877305-2020-05-14
  26. Peshekhonova L.K., Peshekhonov D.V., Krasyukov P.A. Clinical effectiveness of drugs Osteomed, Osteomed Forte, Osteo-Vit D3 in patients with secondary osteoporosis in rheumatoid arthritis. Phys. 2020; 4: 68–74. https://doi.org/10.29296/25877305-2020-04-12
  27. Prokhorov M., Kislov A., Elistratov D. et al. Effect of Osteomed on consolidation of bone fractures. Phys. 2016; 2: 68–9.
  28. Krivosheev SA, Lobuteva LA, Zakharova O. V. et al. Patient-centered approach to providing medicinal care to gerontological patients in ophthalmic practice. Advances in Gerontology. 2018; 31 (2): 300–5.
  29. Dedov D. V. The use of Osteomed, Osteomed Forte and Osteo-Vit D3 drugs in patients with osteoporosis: comprehensive treatment and prevention of fractures. Phys. 2021; 32 (12): 83–85. doi: 10.29296/25877305-2021-12-14.
  30. Miagkova MA, Skripnikova IA, Shalnova SA, et al. Analysis of the prevalence of clinical risk factors for osteoporotic fractures among urban and rural populations of the Russian Federation (based on ESSE-RF-2 epidemiological study). Preventive Medicine. 2020; 23 (6): 60–8. doi: 10.17116/profmed20202306160
  31. Myagkova MA, Skripnikova IA, Shalnova SA, et al. Associations of 10-year probability of osteoporotic fractures with total cardiovascular risk and cardiovascular disease due to atherosclerosis among urban and rural populations. Preventive Medicine. 2021; 24 (6): 18–27. doi: 10.17116/profmed20212406118
  32. Dedov D.V. Osteoporosis in patients of different age groups: clinical and pathogenetic aspects and treatment with Osteomed, Osteo-Vit D3 and Osteomed Forte. Physician, 2021; (9): 64–67 https://doi.org/10.29296/25877305-2021-09-13
  33. Ershov V. E., Rodionova S. S., Krivova A. V., Zakharov V. P. Demographic trends in the fight against osteoporosis and its consequences. RMJ. 2019; 4: 11–14.
  34. Shurgaya M. A. Disability in old age and scientific substantiation of the strategy to improve medical and social rehabilitation in the Russian Federation: diss. D. in Medicine: 14.02.06. Moscow, 2018.
  35. Dedov D.V. Analysis of the effectiveness of drugs Osteomed and Osteomed Forte in the treatment of osteoporotic fractures of various localization. Physician, 2021; (11): 73–76. https://doi.org/10.29296/25877305-2021-11-15
  36. Romanov D.V., Polikarpochkin A.N., Polikarpochkina E.V. Osteomed Forte in the treatment of patients with ankle injuries. Phys. 2020; 31 (8): 70–4. doi: 10.29296/25877305-2020-08-11
  37. Strukov V., Kislov A., Elistratov D. et al. Personalized approach in the therapy of osteoporosis in the elderly. Phys. 2015; 6: 51–53.
  38. Skripnikova I.A., Guryev A.V., Shalnova S.A. et al. Prevalence of clinical factors used to assess risk of osteoporotic fractures. Preventive Medicine. 2016; 19 (5): 32–40. doi: 10.17116/profmed201619532-40
  39. Belaya JE, Rozhinskaya LY, Grebennikova TA, et al. Summary of the draft federal clinical guidelines on osteoporosis. Osteoporosis and osteopathies. 2020; 23 (2): 4–21. doi: 10.14341/osteo12710
  40. Jones O., V. Strukov, et al. Comorbid osteoporosis: challenges and new therapeutic options. Physician. 2017; 10: 23–26; 11: 25–28.
  41. Yarikov AV, Smirnov II, Pavlinov SE et al. Osteoporosis of the spine: epidemiology, modern methods of diagnosis and principles of treatment. Phys. 2020; 31 (11): 21–8. https://doi.org/10.29296/25877305-2020-11-04
  42. Shishkova V.N., Kosmatova O.V., Skripnikova I.A. et al. Topical issues of diagnosis and therapy of osteoporosis in the practice of the therapist. Medical Business. 2021; 1: 52–61. doi: 10.24412/2071-5315-2021-12284
  43. Strukov V., Elistratov D., Balykova L et al. Effect of Osteomed Forte on hormonal status and course of osteoporosis in women with androgen deficiency in postmenopause. Phys. 2015; (3): 28–32.
  44. Yurova O., Marchenkova L. Experience of using Osteomed Forte dietary supplement in a comprehensive rehabilitation program for patients with distal forearm fracture against systemic osteoporosis. Physician, 2020; (2): 47–52. https://doi.org/10.29296/25877305-2020-02-11
  45. Ismailova O., Eremina N., Strukov V., et al. Clinical and pathogenetic features of chronic generalized periodontitis in women at menopause and its morphometric manifestations against the background of complex therapy with the drug Osteomed Forte. Phys. 2019; (10): 40–43. https://doi.org/10.29296/25877305-2019-10-08
  46. Dedov D.V., Marchenko S.D. Osteoporosis in postmenopausal women: medical and social significance, prevention of fractures with Osteomed and Osteomed Forte drugs. Phys. 2022; 33 (1): 69–73. doi: 10.29296/25877305-2022-01-11.
  47. Marchenkova L. A., Makarova E. В. Possibilities of correction of impaired conditioning and coordination motor abilities in osteosarcopenia using calcium and vitamins D3 and B6 supplements. Phys. 2020; 61–68. doi: 10.29296/25877305-2020-07-12
  48. Marchenkova LA Rehabilitation of patients with fractures against the background of osteoporosis: questions and answers OPINION LEADER (Opinion Leader). 2020; 5 (34): 44–56.
  49. Marchenkova L. A., Makarova E. V., Vasilyeva V.A. et al. Effect of basic therapy with calcium and vitamins D3 and B6 on muscle strength, movement and balance functions in patients with osteoporosis who underwent medical rehabilitation. Issues of Balneology, Physical Therapy, and Physical Therapy. 2020; 97 (1): 25–34. doi: 10.17116/kurort20209701125
  50. Khabibulina M.M. Cardiovascular risk in premenopausal estrogen deficiency. Periods. Yekaterinburg, 2014.
  51. Khabibulina M.M. Impact of hypoestrogenism on quality of life of women with arterial hypertension in premenopause. Cardiology. 2013 Т. 53 № 11 . С. 45-48.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies